Arvinas to present ARV-102 Parkinson’s data at MDS congress

Arvinas (ARVN) reported Phase 1 trial data for ARV-102, showing dose-dependent improvements in eye movement and biomarker changes in Parkinson's patients. The treatment reduced LRRK2 protein levels and showed potential in addressing neuroinflammation. Arvinas plans further clinical evaluation. ARVN shares closed at $7.31, up 1.74% in premarket.

Arvinas (ARVN) reported Phase 1 data for ARV-102, showing dose-related changes in oculomotor function and biomarker reductions in Parkinson’s patients. The 28-day study involved 24 patients and compared 20–80 mg doses to placebo.

Arvinas, Inc. (ARVN) presented Phase 1 trial data for ARV-102, a PROTAC degrader targeting LRRK2, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders. The study showed dose-dependent improvements in eye movement and biomarker changes in Parkinson’s patients, supporting further evaluation. ARV-102 is being developed for neurodegenerative diseases associated with LRRK2 dysregulation.

Arvinas (ARVN) will present Phase 1 clinical trial data for ARV-102, a PROTAC LRRK2 degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders. ARV-102 targets LRRK2, a protein linked to Parkinson’s and PSP. The presentations will include biomarker and oculomotor data. Arvinas is a clinical-stage biotech company focused on protein degradation therapies.

Arvinas Inc. (ARVN) began a Phase 1/2 trial for ARV-6723, a PROTAC targeting HPK1 in advanced solid tumors. The global study will assess safety, pharmacokinetics, and antitumor activity as a monotherapy and with pembrolizumab. Preclinical data showed potent HPK1 degradation and antitumor effects. ARVN stock closed at $7.59, up 0.13% in pre-market trading.

Arvinas (ARVN) reported Q2 2026 revenue of $249.7M, up from $22.4M a year earlier, driven by FDA approval of VEPPANU and a licensing deal with Rigel. The FDA approved VEPPANU, the first PROTAC therapy, for advanced breast cancer. Arvinas licensed global rights to Rigel, generating $50M in milestone revenue and $62.5M in license revenue. The company expects three Phase 1 readouts in the next year. Cash reserves fell to $567.9M from $685.4M due to operational expenses.